1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)
CAS60239-18-1
1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) (CAS 60239-18-1, C16H28N4O8) is supplied by ChemSigma for research and manufacturing, with specification, analytical methods and batch documentation available on request.
- CAS No.
- 60239-18-1
- Formula
- C16H28N4O8
- Mol. weight
- 404.42 g/mol
Chemical Specifications
Identifiers
| CAS number | 60239-18-1 |
|---|---|
| Product name | 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) |
| Chinese name | 1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸 |
| Synonyms | 1,4,7,10-TETRAAZACYCLODODECANE-1,4,7,10-TETRAACETIC ACID |
| Chinese synonyms | 1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸; 1,4,7,10-四氮环十二烷基-1,4,7,10-四乙酸; 轮环藤宁四乙酸/1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸; DOTA(1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸); 1,4,7,10-四氮杂环十二烷-N,N,N,N-四乙酸 |
| Molecular formula | C16H28N4O8 |
| Molecular weight | 404.42 g/mol |
Physical and chemical properties
| Boiling Point | 378.1 ( ℃ ) |
|---|
Applications
Gadoteric acid (trade names Artirem, Dotarem) is a macrocycle-structured gadolinium-based MRI contrast agent. It consists of the organic acid DOTA as a chelating agent, and gadolinium (Gd3+), and is used in form of the meglumine salt.[1] The drug is approved and used in a number of countries worldwide. It is used to assist imaging of blood vessels and of inflamed or diseased tissue where the blood vessels become 'leaky'. It is often used when viewing intracranial lesions with abnormal vascularity or abnormalities in the blood–brain barrier. Its paramagnetic property reduces the T1 relaxation time (and to some extent the T2 and T2* relaxation times) in NMR, which is the source of its clinical utility.
Packaging, Storage & Transport
| Available pack sizes | 5kg, 1kg, 500g, 100g, 50g, 10g |
|---|
Read the current safety data sheet before handling. Packaging can be adapted to the order quantity and destination.
Frequently Asked Questions
What is the CAS number of 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)?
The CAS Registry Number of 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) is 60239-18-1. 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) is also known as 1,4,7,10-TETRAAZACYCLODODECANE-1,4,7,10-TETRAACETIC ACID.
What is the molecular formula and molecular weight of 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)?
The molecular formula of 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) is C16H28N4O8, and its molecular weight is 404.42 g/mol.
What is 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) used for?
Gadoteric acid (trade names Artirem, Dotarem) is a macrocycle-structured gadolinium-based MRI contrast agent. It consists of the organic acid DOTA as a chelating agent, and gadolinium (Gd3+), and is used in form of the meglumine salt.[1] The drug is approved and used in a number of countries worldwide. It is used to assist imaging of blood vessels and of inflamed or diseased tissue where the blood vessels become 'leaky'. It is often used when viewing intracranial lesions with abnormal vascularity or abnormalities in the blood–brain barrier. Its paramagnetic property reduces the T1 relaxation time (and to some extent the T2 and T2* relaxation times) in NMR, which is the source of its clinical utility.
How can I request a quotation for 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)?
Send an inquiry for 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) (CAS 60239-18-1) with the required quantity, target specification, destination country and any documentation requirements. ChemSigma will confirm availability, packaging, lead time and price.
Related Products
Request a Quote for 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)
Tell us the required quantity, target specification, destination country and any documentation requirements. We will confirm availability, packaging, lead time and price.
Need custom synthesis or scale-up? Our group company CKS Technology offers custom synthesis, process development and scale-up.